Fig. 6
Improvement of muscle function in hDPSC-treated CXMDJ. a Monitoring of 15 m running speed (s) during the experimental period. b As an acceleration parameter, the acceleration magnitude (AM) was calculated from the three acceleration vectors measured by 15 m running. Hardly detectable ratio of higher AM value (> 10,000 mG) was obtained, which was calculated by dividing the total number of AM from the number of higher AM value (> 10,000 mG) in all groups. c Tetanic force estimated on hindlimbs of dogs. The graph shows the summary statistics of force change relative to baseline values 5 weeks after the final injection. d Ejection fraction (EF) values were calculated using echocardiographic parameters post-transplantation (normal dogs, 14103MN and 12201MN; control DMD, 13303MA, 13802MA, and 14102MA; and hDPSCs-DMD, 12205MA, 13201MA, and 13304MA). All data are represented as mean ± SD and statistical differences between normal and control DMD dogs (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001), control DMD and hDPSCs-DMD (#P < 0.05, ##P < 0.01, ###P < 0.001, and ####P < 0.0001), multiple t test and one-way ANOVA